The latest from BioStock
Read BioStock's newsletter for v.22 here.
Watch the latest episode of The IPO round in the banner below!
Morning news
reports positive preclinical results with uTREAT in aggressive brain cancer. Read more.
Vicore announces further strengthening of patent protection for C21. Read more.
Supplement to the offer document regarding TomEQT Privates mandatory bid to the shareholders of Emplicure has been published. Read more.
The exercise period for warrants series TO 2 in Qlife Holding starts today. Read more.
Last day to shop in BergGenBios Subscription rights are today, June 7th. Read more.
Amgen reports promising results with Lumikras in combination with chemotherapy. Read more.
Nexstim receives a NBS 5+system order from a new American customer. Read more.
FluoGuide announces positive results from the Phase IIa study of FG001 in lung cancer. Read more.
Medim is holding a webcast in connection with the TO6 warrant. Read more.
A board member in Realheart resigns at his own request. Read more.
Last week passed BioStock Life Science Spring Summit off the shelf!
See all the presentations via the banner below:
Invitations:
Interim reports:
Communiqués:
Flagging, insider trading changes in equity:
Aqua Bio Technology Novo Nordisk OptoMed
News since Monday lunch
Idogen's The board of directors proposes that liquidation not be decided at the annual general meeting on June 8. Read more.
Carbiotix has published the outcome of the rights issue. Read more.
Dicot has entered into an agreement to secure the redemption of warrants of series TO 4 for an additional approximately SEK 13,4 million. Read more.
The board of directors Emplicure has spoken out on the occasion of TomEQT Privates mandatory bid. Read moreThe company has also changed the date for its quarterly report 2 to August 29. Read more.
Alligator Bioscience presented the latest clinical data from the phase II OPTIMIZE-1 study with mitazalimab in pancreatic cancer at ASCO's annual meeting 2023. Read more.
Trading in subscription rights in Diamyd Medicals The new issue has been stopped. Read more.
Nordic Nanovector has acquired Thor Medical in radionuclide therapies. Read more.
AstraZeneca Datopotamab deruxtecan showed promising tumor response in the phase Ib study TROPIN-Lung02 in patients with non-small cell lung cancer. Read more. Enhertu demonstrated clinical and durable response in patients with solid tumors expressing HER2. Read more.
Ziccum has updated about CEPI-application. Read more.
AcuCort participating in Cinema International Convention 2023. Read more.
BergenBio has presented data with Bemcentinib during ASCO. Read more.
Nexstim has received a NBS System-order from a Finnish hospital. Read more.
Delay in trade with Brain+ shares have been announced. Read more.
Recipharm has published a statement from Arranta Cinema after the settlement with Thermo Fisher. Read more.
Observe Medical has invited you to a company presentation. Read more.
Zealand Pharma will participate in upcoming conferences. Read more.
Genmab will participate in a fireside chat at Goldman Sachs 44th Annual Global Healthcare Conference. Read more.
A presentation on Euroanaesthesia 2023 confirms the quality of Senzimes TetraGraphs new algorithm. Read more.
A high-profile doctor and entrepreneur participates in Stenocares ongoing issue. Read more.
This morning's price development
Winner: Idogen 104,8%, Cline Scientific 21,2%, Initiator Pharma 19,3%, ExpreS2ion Biotech Holding 11,5%, BiBBInstruments 11,3%
Förlorare: QLife Holding -39,1%, Bonzun -14,2%, Bioservo Technologies -13,9%, OncoZenge -11,9%, ADDvise Group -9,3%
Index: OMSX30 2 305%, Healthcare 0,56%